3 Stocks Pushing The Drugs Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Drugs industry as a whole closed the day up 0.3% versus the S&P 500, which was unchanged. Laggards within the Drugs industry included ImmuCell ( ICCC), down 2.8%, Prima Biomed ( PBMD), down 1.8%, Evoke Pharma ( EVOK), down 2.6%, Ruthigen ( RTGN), down 3.5% and Palatin Technologies ( PTN), down 2.4%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

Palatin Technologies ( PTN) is one of the companies that pushed the Drugs industry lower today. Palatin Technologies was down $0.02 (2.4%) to $0.86 on average volume. Throughout the day, 149,459 shares of Palatin Technologies exchanged hands as compared to its average daily volume of 116,700 shares. The stock ranged in price between $0.85-$0.88 after having opened the day at $0.87 as compared to the previous trading day's close of $0.88.

Palatin Technologies has a market cap of $36.4 million and is part of the health care sector. Shares are up 20.5% year-to-date as of the close of trading on Tuesday. Currently there are 3 analysts who rate Palatin Technologies a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

How to Trade Today's Most Active Stocks -- Ford, Palatin, More

Palatin Female Libido-Boosting Shot Fails Crucial Sex Frequency Test

Insider Trading Alert - AEL, PTN And BSX Traded By Insiders

Palatin Technologies (PTN) Stock Up After FDA Approval of 'Female Viagra'

Palatin Technologies (PTN) Stock Climbing on FDA Approval of 'Female Viagra'